Abstract: The invention relates to the imidazole derivatives as selective antagonistic substances against muscarinic acetylcholine and provides imidazole derivatives represented by a general formula (1) or (2) ##STR1## [wherein R.sub.1 is a phenyl group which may have substituent or thienyl group, R.sub.2 is a cyano group, a carboxyl group, CONR.sub.7 R.sub.8 group (wherein R.sub.7 and R.sub.8 each independently represent hydrogen atom or lower alkyl group, or R.sub.7 and R.sub.8 may form a ring by alkylene chain which may contain hetero atom) or COOR.sub.9 group (wherein R.sub.9 is a lower alkyl group), R.sub.3 is a hydrogen atom or lower alkyl group, R.sub.4, R.sub.5 and R.sub.6 each independently represent hydrogen atom, lower alkyl group which may have substituent or cycloalkyl groups, or may form a condensed ring at the positions of R.sub.5 and R.sub.6 with benzene ring, R.sub.10 is a lower alkyl group or an aralkyl group which may have substituent, m is an integer from 1 to 6, and z is a halogen atom].

Abstract: The invention relates to the imidazole derivatives as selective antagonistic substances against muscarinic acetylcholine and provides imidazole derivatives represented by a general formula (1) or (2) ##STR1## ?wherein R.sub.1 is a phenyl group which may have substituent or thienyl group, R.sub.2 is a cyano group, a carboxy group, CONR.sub.7 R.sub.8 group (wherein R.sub.7 and R.sub.8 each independently represent hydrogen atom or lower alkyl group, or R.sub.7 and R.sub.8 may form a ring by alkylene chain which may contain hetero atom) or COOR.sub.9 group (wherein R.sub.9 is a lower alkyl group), R.sub.3 is a hydrogen atom or lower alkyl group, R.sub.4, R.sub.5 and R.sub.6 each independently represent hydrogen atom, lower alkyl group which may have substituent or cycloalkyl groups, or may form a condensed ring at the positions of R.sub.5 and R.sub.6 with benzene ring, R.sub.10 is a lower alkyl group or aralkyl group which may have substituent, m is an integer from 1 to 6, and Z is a halogen atom!.

Abstract: Imidazolidinone derivatives represented by a following general formula (1) or pharmacologically permissible acid addition salts with cholinergic activity (muscarine M.sub.1 activity) provide compounds useful for the therapy of senile dementia. ##STR1## (wherein R denotes a lower alkyl group which may be substituted by halogen, or the like, R.sup.1 and R.sup.2 denote identically or differently hydrogen atoms or lower alkyl groups, R.sup.3 denotes a formula ##STR2## (wherein R.sup.4 denotes a lower alkyl group which may be substituted by halogen, or the like, q denotes 0 to 3, and R.sup.5 denotes a hydrogen atom or the like), m and n denote 0 to 3, p denotes 1 to 3, and X denotes an oxygen atom or sulfur atom).

Abstract: An optically active imidazolidinone derivative represented by general formula (1), having a cholinergic activity (a muscarine M.sub.1 activity) and being useful for treating senile dementia, a pharmacologically acceptable acid-addition salt thereof, and a process for producing the same, wherein R and R.sup.1 may be the same or different and each represents hydrogen, halogen, optionally halogenated lower alkyl, lower alkoxy, lower alkylthio, lower alkoxycarbonyl, nitro, amino or cyano; and n represents 1 to 4.

Abstract: Disclosed are peptides which have amino acid sequences consisting of 15 to 26 amino acid constituents and have phospholipase A.sub.2 -inhibiting activity.

Abstract: Isoindolin-1-one compounds represented by the following formula (I); ##STR1## {wherein n represents an integer of 1 to 6; m represents 0 or 1; R.sub.1, R.sub.2 and R.sub.3 are each independently hydrogen or lower alkyl, and when m is 1, R.sub.1 and one of R.sub.2 and R.sub.3 may form a five-membered or six-membered ring over N atom; X represents hydrogen or hydroxy; Ar represents naphthyl, pyridyl or substituted phenyl represented by the formula (II); Ar and X may form a lactone ring; ##STR2## [wherein Y represents carboxyl, lower alkoxycarbonyl, carbamoyl, N,N-lower alkyl-substituted carbamoyl or amino represented by the formula (III): ##STR3## (wherein R.sub.6 and R.sub.7 are each independently hydrogen, lower alkyl or lower alkanoyl); R.sub.4 and R.sub.5 are each independently hydrogen, lower alkyl, cyano or halogen]} or a pharmaceutically acceptable acid addition salt or metal salt thereof have an excellent antiarrhythmic activity.